Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul;22(7):1427-1435.e6.
doi: 10.1016/j.cgh.2024.03.017. Epub 2024 Apr 5.

Effects of Food Insecurity on Hepatic Steatosis and Fibrosis in People With HIV

Collaborators, Affiliations

Effects of Food Insecurity on Hepatic Steatosis and Fibrosis in People With HIV

Ani Kardashian et al. Clin Gastroenterol Hepatol. 2024 Jul.

Abstract

Background & aims: Food insecurity (FI) is a risk factor for nonalcoholic fatty liver disease (NAFLD) and advanced fibrosis in the general population, but its impact on liver disease in people with HIV (PWH) is unknown.

Methods: We examined the association of FI with prevalence of NAFLD and fibrosis in a diverse cohort of PWH. PWH aged ≥ 18 years on antiretroviral therapy, HIV RNA <200 copies/mL, and without other known liver diseases were screened for NAFLD (controlled attenuated parameter ≥263 decibels/meter) and advanced fibrosis (liver stiffness measurement ≥11 kilopascals) by vibration controlled transient elastography at 8 U.S.

Centers: Participants were categorized as food insecure using the Six-Item Short Form Household Food Security Survey. We used multivariable logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) of NAFLD and advanced fibrosis by FI status.

Results: Among 654 PWH, NAFLD was present in 348 (53%) and advanced fibrosis in 41 (6%). FI was present in 203 of participants (31%), including 97/348 with NAFLD (28%) and 18/41 with advanced fibrosis (44%). In multivariable analysis, FI was associated with lower odds of NAFLD (OR, 0.57; 95% CI, 0.37-0.88) and a greater, but nonsignificant, odds of advanced fibrosis (OR, 1.38; 95% CI, 0.65-2.90). We identified a significant interaction between FI and diabetes (P = .02) on fibrosis risk, with greater odds of fibrosis among food insecure PWH and diabetes (OR, 3.83; 95% CI, 1.15-12.73) but not among food insecure nondiabetics (OR, 1.12; 95% CI, 0.47-2.98).

Conclusions: FI is highly prevalent among PWH and associated with lower odds of NAFLD, and among PWH with diabetes, there is greater odds of advanced fibrosis. FI may contribute to hepatic fibrosis through mechanisms other than steatosis in PWH.

Keywords: AIDS; Fatty Liver; Food Security; HIV; Liver Disease; Liver Health Outcomes; MASLD; Social Determinants of Health.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest:

Dr. Kardashian: None for this paper. For full disclosure, consulting: Gilead.

Dr. Audrey Lloyd: None for this paper. For full disclosure, her institution has received research grant support from Gilead Sciences and AbbVie.

Dr. Susanna Naggie: declares no conflicts of interest.

Dr. Mark S. Sulkowski: declares no conflicts of interest.

Dr. Tinsay Woreta: declares no conflicts of interest.

Dr. Jordan E. Lake: declares no conflicts of interest.

Dr. Sonya Heath: declares no conflicts of interest.

Dr. Jennifer C. Price: None for this paper. She has received research grant support from Gilead Sciences, AbbVie, VIR, Genentech, and Zydus.

Laura Wilson, Dr. Eduardo Vilar Gomez and Holly Crandall declare no conflicts of interest.

Dr. Chalasani: None for this paper. For full disclosure, he has ongoing consulting agreements with Madrigal, Zydus, Ventyx, Pfizer, GSK, Merck, Altimmune, and Foresite. He has research support from DSM and Exact Sciences. He has equity ownership in Avant Sante Therapeutics, a contract research organization.

Dr. Gawrieh consulting: TransMedics, Pfizer. Research grant support: Viking and Zydus,

Dr. Sterling declares none for this paper. For full disclosure, he has research support form Gilead, AbbVie, Abbott, and Roche, has served on a DSMB for Pfizer, AskBio

Dr. Loomba serves as a consultant to Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns Pharmaceuticals and Viking Therapeutics. RL has stock options in 89bio and Sagimet Biosciences. In addition, his institutions received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Pfizer, Sonic Incytes and Terns Pharmaceuticals. Co-founder of LipoNexus Inc.

Figures

Figure 1.
Figure 1.
Odds of NAFLD (≥263 dB/m)* by Household Food Security Survey score** *Covariate-adjusted logistic regression includes age, sex at birth, race-ethnicity, educational levels, type 2 diabetes, BMI, physical activity **Score ranges from 0 to 6 (0 represents high food security and 6 represents very low food security)

References

    1. Michel M, Labenz C, Wahl A, et al. Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV. AIDS. 2022;36(12):1665–1674. - PMC - PubMed
    1. Michelotti GA, Machado MV, & Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013;10:656–665. - PubMed
    1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023;79:1542–1556. - PubMed
    1. Kalligeros M, Vassilopoulos A, Shehadeh F, et al. Prevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living With HIV Monoinfection: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2023;21:1708–1722. - PubMed
    1. Campos-Varela I, Dodge JL, Terrault NA, Brandman D, & Price JC. Nonviral liver disease is the leading indication for liver transplant in the United States in persons living with human immunodeficiency virus. Am J Transplant. 2021:doi: 10.1111/ajt.16569. - DOI - PMC - PubMed